CME Group (NASDAQ:CME) Given New $266.00 Price Target at The Goldman Sachs Group

Posted by Defense World Staff on Feb 10th, 2026

CME Group (NASDAQ:CME – Free Report) had its target price lifted by The Goldman Sachs Group from $264.00 to $266.00 in a research report released on Monday morning,MarketScreener reports. They currently have a sell rating on the financial services provider’s stock.

Several other equities research analysts have also recently issued reports on CME. Weiss Ratings reaffirmed a “buy (b+)” rating on shares of CME Group in a research note on Monday, December 29th. Raymond James Financial reduced their price objective on shares of CME Group from $311.00 to $310.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Royal Bank Of Canada lifted their target price on shares of CME Group from $295.00 to $302.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on CME Group from $262.00 to $266.00 and gave the company an “underweight” rating in a report on Thursday, February 5th. Finally, Jefferies Financial Group decreased their price objective on CME Group from $304.00 to $302.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, CME Group has a consensus rating of “Hold” and an average target price of $297.59.

Read Our Latest Stock Report on CME

CME Group Stock Performance

CME Group stock opened at $307.24 on Monday. CME Group has a fifty-two week low of $239.70 and a fifty-two week high of $307.84. The company has a market capitalization of $110.79 billion, a price-to-earnings ratio of 27.53, a PEG ratio of 3.29 and a beta of 0.27. The stock has a fifty day moving average of $277.46 and a two-hundred day moving average of $273.21. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.02 and a current ratio of 1.03.

CME Group (NASDAQ:CME – Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The financial services provider reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.75 by $0.02. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.64 billion. CME Group had a return on equity of 14.65% and a net margin of 62.45%.The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.52 earnings per share. On average, analysts anticipate that CME Group will post 10.49 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director William R. Shepard purchased 251 shares of the company’s stock in a transaction on Tuesday, December 30th. The stock was bought at an average cost of $278.37 per share, for a total transaction of $69,870.87. Following the completion of the purchase, the director directly owned 258,710 shares of the company’s stock, valued at $72,017,102.70. The trade was a 0.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dennis Suskind sold 748 shares of CME Group stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $300.00, for a total value of $224,400.00. Following the completion of the transaction, the director directly owned 2,699 shares in the company, valued at $809,700. This represents a 21.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of CME Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jessup Wealth Management Inc increased its position in shares of CME Group by 0.5% in the second quarter. Jessup Wealth Management Inc now owns 7,969 shares of the financial services provider’s stock worth $2,197,000 after acquiring an additional 36 shares in the last quarter. First Horizon Advisors Inc. boosted its position in CME Group by 0.7% during the 2nd quarter. First Horizon Advisors Inc. now owns 5,269 shares of the financial services provider’s stock worth $1,453,000 after purchasing an additional 36 shares during the period. MBM Wealth Consultants LLC boosted its position in CME Group by 2.7% during the 2nd quarter. MBM Wealth Consultants LLC now owns 1,422 shares of the financial services provider’s stock worth $392,000 after purchasing an additional 37 shares during the period. West Family Investments Inc. increased its holdings in CME Group by 1.2% in the 3rd quarter. West Family Investments Inc. now owns 3,062 shares of the financial services provider’s stock valued at $827,000 after purchasing an additional 37 shares in the last quarter. Finally, Asset Dedication LLC raised its position in CME Group by 64.9% in the fourth quarter. Asset Dedication LLC now owns 94 shares of the financial services provider’s stock valued at $26,000 after purchasing an additional 37 shares during the period. Institutional investors and hedge funds own 87.75% of the company’s stock.

Key CME Group News

Here are the key news stories impacting CME Group this week:

Positive Sentiment: Large institutional buy — Intermede Investment Partners disclosed a new ~$77.8M position in CME on a 13F filing, signaling meaningful institutional demand that can support the share rally. Fund Update: New $77.8M $CME stock position opened by Intermede Investment Partners Ltd
Positive Sentiment: Product / distribution win — FlexTrade integrated CME’s FX Spot+ and EBS Market offerings into its FlexFX system, expanding CME’s distribution and potential FX flow capture. That supports revenue growth in FX products. FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading
Neutral Sentiment: Valuation note — A Seeking Alpha piece argues CME’s fundamentals are strong but the stock looks “fully valued,” reinforcing mixed views among investors about near-term upside vs. stretched multiples. CME Group’s Strength Is Clear, But The Stock Looks Fully Valued
Negative Sentiment: Insider selling — Director Dennis Suskind sold 748 shares (~21.7% of his holding) for ~$224k; this is one of several recent insider sales disclosed and can be interpreted as a modest negative signal by some investors. SEC Form 4: Dennis Suskind sale
Negative Sentiment: Analyst stance — Goldman Sachs kept a sell rating on CME while nudging its price target to $266, which reinforces downside views among some institutional investors and may cap upside despite bullish flows. Goldman Sachs adjusts price target on CME Group to $266 from $264, maintains sell rating

CME Group Company Profile

(Get Free Report)

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.